| Identification | Back Directory | [Name]
Adenosine, N-[6-[[4-[5-amino-4-benzoyl-3-[3-(trifluoromethyl)phenyl]-2-thienyl]benzoyl]amino]hexyl]- | [CAS]
1582751-84-5 | [Synonyms]
VCP746
Adenosine, N-[6-[[4-[5-amino-4-benzoyl-3-[3-(trifluoromethyl)phenyl]-2-thienyl]benzoyl]amino]hexyl]- | [Molecular Formula]
C41H40F3N7O6S | [MOL File]
1582751-84-5.mol | [Molecular Weight]
815.86 |
| Chemical Properties | Back Directory | [density ]
1.50±0.1 g/cm3(Predicted) | [storage temp. ]
2-8°C | [solubility ]
DMSO: 2mg/mL, clear | [form ]
powder | [pka]
13.12±0.70(Predicted) | [color ]
white to beige | [InChIKey]
XLCQNEBOQXQNGA-IYRWRCLLSA-N | [SMILES]
O=C(C1=CC=C(C=C1)C2=C(C(C(C3=CC=CC=C3)=O)=C(S2)N)C4=CC=CC(C(F)(F)F)=C4)NCCCCCCNC5=C6N=CN(C6=NC=N5)[C@@H]7O[C@@H]([C@H]([C@H]7O)O)CO |
| Hazard Information | Back Directory | [Biological Activity]
VCP746 is an adenosine receptor A1 (A1AR) agonist composed of adenosine linked to the A1AR positive allosteric modulator VCP171allowing greatly improved affinity (KI = 58.9 nM vs. 2.95 μM/adenosine & 1.55 μM/VCP171) and potency (GTPγS binding induction EC50 = 0.89 nM vs. 93.3 nM/adenosine & 977 nM/VCP171; hA1AR-CHO membrane) via bitopic receptor engagement with both orthosteric and allosteric sitesas well as biased agonism toward inhibition of forskolin-stimulated cAMP over ERK1/2 phosphorylation (hA1AR-CHO) without hA3AR agonist potency. VCP746 protects against ischemia/hypoxia-induced death of r at neonatal ventricular cardiomyocytes (1 μM) and embryonic cardiomyoblasts (300 nM) without affecting isolated r at atrial heart rate. |
|
|